Nanostructured lipid carrier in photodynamic therapy for the treatment of basal-cell carcinoma

Qidwai, Afreen; Khan, Saba; Shadab,; Fazil, Mohammad; Baboota, Sanjula; Narang, Jasjeet Kaur; Ali, Javed

doi:10.3109/10717544.2016.1165310

Cited by 44 publications

(18 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The method does not require any special equipment or energy for production of NLC; hence it is simple to commercially scale up the technique. 22,27,28…”

Section: Microemulsion Methodsmentioning

confidence: 99%

Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery

Chauhan¹,

Yasir

Verma³

et al. 2020

Adv Pharm Bull

293

145

View full text Add to dashboard Cite

Nanostructured lipid carriers (NLCs) are novel pharmaceutical formulations which are composed of physiological and biocompatible lipids, surfactants and co-surfactants. Over time, as a second generation lipid nanocarrier NLC has emerged as an alternative to first generation nanoparticles. This review article highlights the structure, composition, various formulation methodologies, and characterization of NLCs which are prerequisites in formulating a stable drug delivery system. NLCs hold an eminent potential in pharmaceuticals and cosmetics market because of extensive beneficial effects like skin hydration, occlusion, enhanced bioavailability, and skin targeting. This article aims to evoke an interest in the current state of art NLC by discussing their promising assistance in topical drug delivery system. The key attributes of NLC that make them a promising drug delivery system are ease of preparation, biocompatibility, the feasibility of scale up, non-toxicity, improved drug loading, and stability.

show abstract

“…The method does not require any special equipment or energy for production of NLC; hence it is simple to commercially scale up the technique. 22,27,28…”

Section: Microemulsion Methodsmentioning

confidence: 99%

Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery

Chauhan¹,

Yasir

Verma³

et al. 2020

Adv Pharm Bull

293

145

View full text Add to dashboard Cite

show abstract

“…Primary emulsions were prepared by melting and agitating the lipid mixture using a magnetic stirrer, to which different surfactants were added followed by drop-wise addition of double-distilled water. The preparations obtained were observed for clarity and homogeneity [24].…”

Section: Screening Of Excipientsmentioning

confidence: 99%

“…The ABTSþ assay is predominantly interesting as the absorption maxima at a wavelength of 734 nm exclude colour interference[35]. The IC 50 value of optimized SFN-loaded NLC formulation and SFN solution for ABTSþ was found to be 62 24. ± 4.54 lg Trolox equivalent and 78.98 ± 4.32 lg Trolox equivalent, respectively.…”

mentioning

confidence: 99%

Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments

Soni

Rizwanullah

Kohli

2017

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

In the present study, sulforaphane (SFN)-loaded nanostructured lipid carriers (NLC) were developed and optimized for improved oral efficacy against cancer. The SFN-loaded NLC formulation was developed by melt emulsification ultrasonication technique and optimized by Box-Behnken statistical design. The optimized SFN-loaded NLC formulation composed of precirol ATO 5 (solid lipid) and vitamin E (liquid lipid) as lipid phase (3% w/v), poloxamer 188 (1%) and Tween 80 (1%) as surfactant. The mean particle size, polydispersity index, zeta potential, entrapment efficiency (%) and drug loading (%) of optimized SFN-loaded NLC formulation was observed to be 145.38 ± 4.46 nm, 0.181 ± 0.023, -25.12 ± 2.36 mV, 84.94 ± 3.82% and 14.82 ± 3.46%, respectively. In vitro drug release studies showed that the release of SFN from optimized NLC formulation was significantly higher (86.52 ± 5.48%) compared to SFN suspension (38.47 ± 5.52%) up to 24 h. Ex vivo gut permeation studies revealed a very good enhancement in permeation of drug present in the NLC compared to plain SFN solution and were further confirmed by CLSM. MTT assay in different cancer cell lines showed that the optimized SFN-loaded NLC formulation exhibited significantly improved (p < .05) cytotoxicity compared to free SFN solution. SFN-loaded NLC formulation showed significantly improved antioxidant activity compared to free SFN solution. Furthermore, pharmacokinetic study on albino Wistar rats showed 5.04-fold increase in relative oral bioavailability with NLC (p < .05) compared to SFN suspension. Therefore, NLC represents a great potential for improved efficacy of SFN after oral administration.

show abstract

“…Improved skin deposition has been demonstrated for a number of compounds including tacrolimus [143,144], psoralen [145], methotrexate [146], miconazole nitrate [147], fluocinolone acetonide [148] and 5-amino levulinic acid [149].…”

Section: Nanostructured Lipid Carriers (Nlc)mentioning

confidence: 99%

Topical and cutaneous delivery using nanosystems

Roberts

Mohammed

Pastore

et al. 2017

Journal of Controlled Release

222

113

View full text Add to dashboard Cite

The goal of topical and cutaneous delivery is to deliver therapeutic and other substances to a desired target site in the skin at appropriate doses to achieve a safe and efficacious outcome. Normally, however, when the stratum corneum is intact and the skin barrier is uncompromised, this is limited to molecules that are relatively lipophilic, small and uncharged, thereby excluding many potentially useful therapeutic peptides, proteins, vaccines, gene fragments or drug-carrying particles. In this review we will describe how nanosystems are being increasingly exploited for topical and cutaneous delivery, particularly for these previously difficult substances. This is also being driven by the development of novel technologies, which include minimally invasive delivery systems and more precise fabrication techniques. While there is a vast array of nanosystems under development and many undergoing advanced clinical trials, relatively few have achieved full translation to clinical practice. This slow uptake may be due, in part, to the need for a rigorous demonstration of safety in these new nanotechnologies. Some of the safety aspects associated with nanosystems will be considered in this review.

show abstract

Nanostructured lipid carrier in photodynamic therapy for the treatment of basal-cell carcinoma

Cited by 44 publications

References 22 publications

Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery

Nanostructured Lipid Carriers: A Groundbreaking Approach for Transdermal Drug Delivery

Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments

Topical and cutaneous delivery using nanosystems

Contact Info

Product

Resources

About